Oxford Biomedica plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OXB.L research report →
Companywww.oxb.com
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes.
- CEO
- Frank Mathias
- IPO
- 1996
- Employees
- 850
- HQ
- Oxford, GB
Price Chart
Valuation
- Market Cap
- $749.70M
- P/E
- -21.78
- P/S
- 4.44
- P/B
- 7.18
- EV/EBITDA
- -49.18
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 39.10%
- Op Margin
- -19.88%
- Net Margin
- -17.85%
- ROE
- -48.56%
- ROIC
- -13.00%
Growth & Income
- Revenue
- $168.74M · 31.01%
- Net Income
- $-30,128,000 · 30.24%
- EPS
- $-0.27 · 35.71%
- Op Income
- $-33,543,000
- FCF YoY
- 82.43%
Performance & Tape
- 52W High
- $962.00
- 52W Low
- $291.00
- 50D MA
- $605.46
- 200D MA
- $640.92
- Beta
- 1.09
- Avg Volume
- 336.51K
Get TickerSpark's AI analysis on OXB.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our OXB.L Coverage
We haven't published any research on OXB.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OXB.L Report →